Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
ABEO EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Abeona Therapeutics Inc.NASDAQ: ABEO
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.3, compared with -$0.24 a year earlier. Trailing-twelve-month EPS (Diluted) was $0.95.
Context
- EPS (Diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 6 analysts of -$0.96 (-194.9%) for the fiscal year ending Dec 2026, a slowdown from the +165.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.3+16.7% QoQ
- Last fiscal yearDec 2025
- $1.01+165.2% YoY
- LTMMar 2026
- $0.95+199.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -25.0% | -113.5% | -88.5 pp |
| 1 year | +165.2% | -194.9% | -360.1 pp |
| 3-year CAGR | — | -45.9% | — |
| 5-year CAGR | +11.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- 1.01 USD
- Year-over-year change
- +165.2%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.01 | +165.2% |
| FY2024 | 2024-12-31 | (1.55) | +38.7% |
| FY2023 | 2023-12-31 | (2.53) | +54.2% |
| FY2022 | 2022-12-31 | (5.53) | +74.3% |
| FY2021 | 2021-12-31 | (21.50) | — |
EPS (Diluted) vs competitors
How ABEO compares with its peers on the latest reported figures
- ABEO's LTM Mar 2026 EPS (Diluted) of $0.95 is the highest of the 10 companies compared; the peer median is -$0.87.
- Its year-over-year change of +199.5% is the highest of 10, against a peer median of +14.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.95 | +199.5% | — | |
| LTM Mar 2026 | $0.48 | -37.8% | +210.9% | |
| LTM Mar 2026 | -$0.47 | +59.5% | — | |
| LTM Mar 2026 | -$0.58 | +90.9% | — | |
| LTM Mar 2026 | -$0.59 | +14.6% | — | |
| LTM Mar 2026 | -$0.87 | +60.7% | — | |
| LTM Mar 2026 | -$1.17 | +14.6% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$1.35 | +23.3% | — |
| LTM Mar 2026 | -$1.98 | -35.6% | — | |
| LTM Mar 2026 | -$2.83 | -11.9% | — | |
| Peer median (excluding ABEO) | -$0.87 | +14.6% | +210.9% | |
Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3M | 1.41M | 3.5M | 0 | 5.82M |
| Cost of Revenue | 0 | 450K | 1.61M | 2.91M | 1.53M |
| Gross Profit | 3M | 964K | 1.9M | (2.91M) | 4.29M |
| Gross Margin | 100.0% | 68.2% | 54.1% | — | 73.7% |
| Research & Development | 38.73M | 28.97M | 31.09M | 34.36M | 26.81M |
| Selling, General & Admin | 21.64M | 17.26M | 19M | 29.85M | 65.03M |
| Operating Expenses | 92.84M | 51.88M | 49.03M | 61.3M | 93.74M |
| Depreciation & Amortization | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| EBITDA | (76.82M) | (34.38M) | (50.57M) | (56.62M) | 78.59M |
| EBITDA Margin | -2560.5% | -2431.6% | -1444.9% | — | 1350.3% |
| Operating Income | (89.84M) | (50.92M) | (47.14M) | (64.21M) | (89.45M) |
| Operating Margin | -2994.5% | -3600.8% | -1346.7% | — | -1536.9% |
| Interest Income | 40K | 431K | 2.12M | 4.25M | 5.56M |
| Interest Expense | 3.66M | 736K | 418K | 4.21M | 3.74M |
| Other Income / Expenses | 4.9M | 11.22M | (7.05M) | 477K | 160.73M |
| Income Before Tax | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.28M |
| Pre-Tax Margin | -2831.2% | -2807.4% | -1548.2% | — | 1224.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 100K |
| Net Income | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.18M |
| Net Margin | -2831.2% | -2807.4% | -1548.2% | — | 1223.1% |
| EPS (Basic) | (21.50) | (5.53) | (2.53) | (1.55) | 1.34 |
| EPS (Diluted) | (21.50) | (5.53) | (2.53) | (1.55) | 1.01 |
| Weighted Avg Shares | 3.94M | 7.86M | 21.38M | 41.05M | 52.95M |
| Weighted Avg Shares (Diluted) | 3.94M | 7.86M | 21.38M | 41.05M | 66.14M |
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.